Nevertheless, even if IFN-free DAA therapy is prioritized to those with advanced liver disease, it is possible that IFN-based treatment uptake among those with less advanced disease will remain high given historically high rates of uptake among HIV-coinfected MSM. This evidence concerns the gene IFNA1 and liver disorder.